logo
Vizient Hosts Congressional Briefing on the Complexities of Hospital Financing

Vizient Hosts Congressional Briefing on the Complexities of Hospital Financing

Business Wire15-05-2025

IRVING, Texas--(BUSINESS WIRE)--Yesterday on Capitol Hill, Vizient, Inc. hosted a congressional policy briefing titled, "Hospitals' Financial Health: The Complex Ecosystem of Provider Reimbursement," at the Rayburn House Office Building. The event featured remarks from Rep. Dave Min (D-CA) and drew an engaged audience of congressional staff and industry stakeholders. While unable to attend in person, House Agriculture Committee Chairman Glenn 'GT' Thompson (R-PA) and Rep. Lou Correa (D-CA) shared remarks in support of the briefing. The discussion focused on how hospitals are navigating a complex financial environment shaped by shifting reimbursement models, evolving policy changes, and increasing care demands.
'Academic medical centers like UCI Health are training future clinicians while delivering essential care,' said Rep. Min (D-CA). 'However, growing financial pressures, especially around Medicaid reimbursement, threaten their ability to keep their doors open. We need to advance policies that ensure reliable reimbursement and protect access to care for all Californians.'
'As a former therapist and licensed nursing home administrator, I've seen first-hand the essential need for access to quality care,' said Rep. Thompson (R-PA). 'Reliable health systems are necessary for the health and economic well-being of rural communities. I look forward to working with all stakeholders to strengthen quality, lower costs, and increase the availability of care.'
'In neighborhoods across Orange County, hospitals are essential for delivering care, supporting jobs, and keeping our families healthy,' said Rep. Correa (D-CA). 'When hospitals in our district face financial strain, the ripple effects are real and immediate. We need strong, common-sense public policy that ensures hard-working American taxpayers have access to the care they need when they need it.'
Moderated by Michael D. Busch, FACHE, senior vice president, member networks at Vizient, the panel featured key healthcare leaders, including:
Stephanie Daubert, Chief Financial Officer, Nebraska Medicine
Steven M. Fontaine, Chief Executive Officer, Penn Highlands Healthcare
Randolph P. Siwabessy, Senior Vice President & Chief Financial Officer, UCI Health & UC Irvine School of Medicine
Panelists discussed the growing financial instability facing hospitals, particularly given the uncertainty around governmental funding. As noted during the briefing, hospitals are a unique combination of public utility, clinical enterprise, and academic mission, which makes their financing inherently complex. Adjusting one policy can unintentionally unravel other parts due to the system's interconnectedness. Panelists also highlighted rising operating costs, persistent labor shortages, delayed reimbursements, and the widening gap between payment rates and the actual cost of care, especially for Medicaid and Medicare patients.
The panel underscored the need for sustainable policy solutions to protect hospital viability and patient access, highlighting priorities such as stabilizing government reimbursement programs, protecting safety net payments and programs and preserving graduate medical education support.
Learn more about Vizient's advocacy and public policy efforts.
About Vizient, Inc.
Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmaceutical company AstraZeneca sues Utah Attorney General over discount medication law
Pharmaceutical company AstraZeneca sues Utah Attorney General over discount medication law

Yahoo

time3 hours ago

  • Yahoo

Pharmaceutical company AstraZeneca sues Utah Attorney General over discount medication law

SALT LAKE CITY () — The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah Insurance Commissioner Jon Pike over a recent law that is intended to allow more pharmacies to have access to drug discount programs. In a lawsuit filed May 23, AstraZeneca alleges that Utah SB 69 is unconstitutional. The law was introduced and passed in the 2025 General Assembly, and it went into effect on May 7. The law prohibits drug manufacturers from restricting pharmacies from working with 340B entities, which help pharmacies and patients access medications at a discounted price. Senator Lee responds to the Trump-Musk feud The 340B Drug Pricing Program is a that 'enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services,' according to the Health Resources and Services Administration (HRSA) website. It means that drug manufacturers participating in Medicaid agree to provide 'outpatient drugs to covered entities at significantly reduced prices.' All organizations need to be registered and enrolled in the 340B program in order to purchase discounted medications. The law that established the 340B Program, Section 340B(a)(4) of the Public Health Service Act, specified certain types of for the program, such as medical centers that serve rural and other underserved communities and clinics that specialize in particular diseases like HIV/AIDS. SB 69 expands the scope, requiring drug manufacturers to provide the discounts to third-party pharmacies that are contracting with 340B entities, and this is what AstraZeneca is claiming is unconstitutional in its lawsuit. Utah House Republicans elect new leadership members The lawsuit states that because price controls 'disincentivize innovation and destabilize markets,' Congress chose to specifically limit the types of organizations that are eligible in Section 340B. The suit notes that for-profit pharmacies like Walgreens or CVS were not included as eligible, and there have already been several federal court cases ruling that block efforts to require drug manufacturers to provide discounts to contracted pharmacies. AstraZeneca claims in its suit that SB 69 'requires pharmaceutical manufacturers to offer 340B-discounted pricing for sales at an unlimited number of contract pharmacies,' expanding 340B discounts to 'an entirely new category of transactions not covered by Section 340B itself.' The suit alleges that SB 69 directly conflicts with federal law requirements, and therefore, it cannot be enforced against Astrazeneca or other drug manufacturers. AstraZeneca is asking the court to declare SB 69 unconstitutional and to order that Utah AG Derek Brown and Insurance Commissioner Jon Pike not enforce the law against AstraZeneca. Musk floats 'The American Party' after Trump tiff Myths VS Facts: What health officials want you to know about the MMR vaccine Good4Utah Road Tour: Willard Bay State Park Lori Vallow Daybell back in court, charged with conspiracy to murder ex nephew-in-law Man charged with assault for allegedly attacking and strangling neighbor Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Activists protest possible Medicaid cuts outside KS Rep. Derek Schmidt's Topeka office
Activists protest possible Medicaid cuts outside KS Rep. Derek Schmidt's Topeka office

Yahoo

time3 hours ago

  • Yahoo

Activists protest possible Medicaid cuts outside KS Rep. Derek Schmidt's Topeka office

TOPEKA (KSNT) — Kansans are speaking out against lawmakers who are voting to cut Medicaid. The GOP-led One Big Beautiful Bill Act passed the US House by a razor thin margin. 215 House members voted to pass it, while 214 voted against it. Local Kansas activists are calling out Rep. Derek Schmidt, a Republican who voted to pass the bill. A group of protesters gathered outside of Schmidt's office in Topeka Thursday afternoon and expressed concerns about cuts to Medicaid. 'Today is life or death,' protester Dillon Warren said. 'We voted someone in there that we shouldn't have. He doesn't support us.' The Congressional Budget Office estimates that if the bill passes, at least 7 million people will lose Medicaid coverage. For that reason, many Kansas voters are making their voices heard. Chiefs and Royals stadium bill deadline approaching as Kansas and Missouri fight for the teams 'We need Medicaid for medical equipment,' protester Rick Macias said. 'These chairs are $200,000 if not more. So, it's very important that Medicaid sticks around.' 27 News reached out to Schmidt, who was unavailable for comment. A spokesperson for the congressman provided 27 News with a written statement. 'Congressman Schmidt is a strong supporter of Medicaid for people the program is designed to help: those who are disabled, in nursing homes, pregnant, raising small children, or otherwise in need. Unfortunately, some states have abused the program by providing benefits to illegal aliens, millions of healthy young adults who choose not to work, or people who are not eligible to receive taxpayer-funded benefits from the program. That is the main reason why Medicaid spending has exploded by more than 50 percent since just 2019: an unsustainable rate of growth that puts benefits for Americans who need them most at risk. By addressing this abuse of the program, Congressman Schmidt is protecting both the traditional Medicaid recipients who rely on benefits and the taxpayers who pay the bills.' Spokesman for Rep. Derek Schmidt For more Capitol Bureau news, click here. Keep up with the latest breaking news in northeast Kansas by downloading our mobile app and by signing up for our news email alerts. Sign up for our Storm Track Weather app by clicking here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating

Yahoo

time4 hours ago

  • Yahoo

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating

Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store